UMIN-ICDS Clinical Trial
| Unique ID issued by UMIN | UMIN000042777 |
|---|---|
| Receipt number | R000048823 |
| Scientific Title | Study on urological cancer diagnosis, prediction for stage and treatment effect by comprehensive serum glycopeptide spectra analysis(prostate cancer, urothelial cancer, renal cell carcinoma) |
| Date of disclosure of the study information | 2023/01/01 |
| Last modified on | 2020/12/17 15:59:30 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Study on urological cancer diagnosis, prediction for stage and treatment effect by comprehensive serum glycopeptide spectra analysis(prostate cancer, urothelial cancer, renal cell carcinoma)
Acronym
Study on urological cancer diagnosis, prediction for stage and treatment effect by comprehensive serum glycopeptide spectra analysis
Scientific Title
Study on urological cancer diagnosis, prediction for stage and treatment effect by comprehensive serum glycopeptide spectra analysis(prostate cancer, urothelial cancer, renal cell carcinoma)
Scientific Title:Acronym
Study on urological cancer diagnosis, prediction for stage and treatment effect by comprehensive serum glycopeptide spectra analysis
Region
| Japan |
Condition
Condition
Urological cancer
Classification by specialty
| Urology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To establish new methods for diagnosing, staging and predicting therapeutic effects of urological cancers (prostate cancer, urothelial cancer, renal cell carcinoma) by comprehensive serum glycopeptide profile analysis.
Basic objectives2
Bio-availability
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Correlation analysis between comprehensive serum glycopeptide profile analysis and diagnosis of the presence or absence of cancer, staging, efficacy for treatment, diagnostic imaging findings, and histopathological findings
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1. Patients suspected with urological cancer, and patients with urological cancer before or after receiving treatment.
2. Patients with benign urological diseases.
3. A person who has received sufficient explanation of this research and obtained informed consent.
Key exclusion criteria
1. Person who are considered as worsen their health condition due to blood test.
2. Person who are regarded as inappropriate for the study by the researcher.
Target sample size
800
Research contact person
Name of lead principal investigator
| 1st name | Masanori |
| Middle name | |
| Last name | Hasegawa |
Organization
Tokai University
Division name
School of Medicine
Zip code
259-1193
Address
143 Shimokasuya, Isehara, Kanagawa
TEL
0463-93-1121
hasem@tsc.u-tokai.ac.jp
Public contact
Name of contact person
| 1st name | Masanori |
| Middle name | |
| Last name | Hasegawa |
Organization
Tokai University
Division name
School of Medicine
Zip code
259-1193
Address
143 Shimokasuya, Isehara, Kanagawa
TEL
0463-93-1121
Homepage URL
hasem@tsc.u-tokai.ac.jp
Sponsor or person
Institute
Tokai University
Institute
Department
Personal name
Funding Source
Organization
Tokai University
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Institutional Review Board for Clinical Research, Tokai University
Address
143 Shimokasuya, Isehara, Kanagawa
Tel
0463-93-1121
tokai-rinsho@ml.tokai-u.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2023 | Year | 01 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2020 | Year | 09 | Month | 14 | Day |
Date of IRB
| 2020 | Year | 09 | Month | 14 | Day |
Anticipated trial start date
| 2020 | Year | 09 | Month | 14 | Day |
Last follow-up date
| 2025 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
none
Management information
Registered date
| 2020 | Year | 12 | Month | 17 | Day |
Last modified on
| 2020 | Year | 12 | Month | 17 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000048823
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
